COMMUNIQUÉS West-GlobeNewswire

Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers
21/10/2025
CPV-104 is the only recombinant Factor H in clinical development and has received EU Orphan Drug Designation for C3G Eleva successfully completed the Single Ascending Dose part of the First-in-Human clinical trial [...]
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
21/10/2025
– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety [...]
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
21/10/2025
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety [...]
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
21/10/2025
Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment 1 Data will be shared with regulatory [...]
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
21/10/2025
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium ; October 21, 2025, 07:30 [...]
Phonak’s AI revolution continues: new Infinio Ultra hearing aids with clearer sound and easier maintenance
21/10/2025
STÄFA, Switzerland, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Phonak , a global leader in innovative hearing solutions, introduces Infinio Ultra, the next step in tackling two core challenges for hearing aid users: speech [...]
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
21/10/2025
WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments [...]
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
21/10/2025
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex [...]
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
21/10/2025
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing [...]
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
21/10/2025
EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American’s continued listing [...]
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
21/10/2025
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing [...]
Healios K.K. to Present at Chardan’s 9th Annual Genetic Medicines Conference
21/10/2025
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the Chardan 9 th Annual Genetic Medicines Conference in New York [...]
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
20/10/2025
Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 NEW YORK and AMSTERDAM, [...]
EMS HEALTH LLC Unveils New E-Commerce Platform NuGeneLabs.com for Holistic Wellness
20/10/2025
Innovative Online Store Offers Comprehensive Health Solutions and Personalized Wellness Products Miami, FL, Oct. 20, 2025 (GLOBE NEWSWIRE) -- EMS HEALTH LLC, a leader in fitness and holistic wellness services, proudly [...]
BRAVE Trauma Therapist Collective Celebrates 3 Years as Leading Community for Trauma Therapists
20/10/2025
Founded by Dr. Jenny Hughes, the online membership community has supported hundreds of trauma therapists worldwide, impacting thousands of trauma survivors HOUSTON, TX, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BRAVE Providers [...]
Hapbee Announces R&D of Three New Frequency Wellness Signals for Hunger Management, Allergy Comfort, and Sexual Vitality; Closes Private Placement and Appoints Director
20/10/2025
After powering millions of wellness sessions globally with its signature Sleep, Focus, Calm, Energy, and Strain Relief signals, Hapbee explores adding three transformative frequencies that can broaden the platform’s [...]
Aurora Spine Announces Proposed Warrant Extension
20/10/2025
CARLSBAD, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today [...]
Bio Usawa Announces Approval of BioUcenta™ by the Rwandan FDA
20/10/2025
BioUcenta™ is the first biosimilar of Lucentis (ranibizumab) approved in Africa KIGALI, Rwanda and SAN FRANCISCO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Rwanda Food and Drugs Authority has granted market approval for Bio [...]
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
20/10/2025
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Cycle Pharmaceuticals Ltd. for Phyrago™ (dasatinib) tablets [...]

Pages